Recombinant Human MICL/CLEC12A Fc Chimera Protein, CF

R&D Systems | Catalog # 10835-ML

R&D Systems
100% Guarantee

Key Product Details

  • R&D Systems CHO-derived Recombinant Human MICL/CLEC12A Fc Chimera Protein (10835-ML)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

CHO

Accession Number

AAI26292.1

Structure / Form

Disulfide-linked homodimer

Applications

Bioactivity
View all MICL/CLEC12A Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human MICL/CLEC12A protein
MD Human IgG1
(Pro100-Lys330)		 IEGR Human MICL/CLEC12A
(Thr67-Ala265)
Accession # AAI26292.1
N-terminus C-terminus

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met

Predicted Molecular Mass

50 kDa

SDS-PAGE

70-85 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human Integrin alpha X beta 2 Protein (Catalog # 5755-AX) is immobilized at 5.00 μg/mL, 100 μL/well, the concentration of Recombinant Human MICL/CLEC12A Fc Chimera (Catalog# 10835-ML) that produces 50% of the optimal binding response is approximately 1.20-12.0 μg/mL.

Scientific Data Images for Recombinant Human MICL/CLEC12A Fc Chimera Protein, CF

Recombinant Human MICL/CLEC12A Fc Chimera Protein Binding Activity.

When Recombinant Human Integrin alpha X beta 2 Protein (5755-AX) immobilized at 5.00 μg/mL, 100 μL/well, the concentration of Recombinant Human MICL/CLEC12A Fc Chimera (Catalog# 10835-ML) that produces 50% of the optimal binding response is approximately 1.20-12.0 μg/mL.

Recombinant Human MICL/CLEC12A Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Human MICL/CLEC12A Fc Chimera (Catalog # 10835-ML) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 70-85 kDa and 140-170 kDa, respectively.

Formulation, Preparation, and Storage

10835-ML
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: MICL/CLEC12A

C-type lectin domain family 12 member A (CLEC12A), also known as C-type lectin-like molecule 1 (CLL1), dendritic cell-associated lectin 2 (DCAL-2), myeloid inhibitory C-type lectin-like receptor (MICL), killer cell lectin like receptor-1 (KLRL1) and CD371, is a member of the C-type lectin receptor superfamily. Of the 17 groups in the superfamily, CLEC12A belongs to group V, which lacks the domain for calcium binding typically found in classical carbohydrate-binding CLECs (1). Mature CLEC12A consists of an extracellular domain (ECD) with a single C-type lectin-like domain, a type II transmembrane domain and a cytoplasmic tail containing an immunoreceptor tyrosine-based inhibition motif (ITIM) (3). Within the ECD, human CLEC12A shares 50% and 47% amino acid sequence identity with mouse and rat CLEC12A, respectively. Human CLEC12A differs from mouse CLEC12A in that it is heavily glycosylated and is found as a monomer rather than a dimer (2). CLEC12A is predominantly expressed in innate immune cells and plays a role in immunotherapy (1-6). CLEC12A preferentially associates with the protein tyrosine phosphatases SHP-1 and SHP-2 but not SHIP. Mechanistic studies with chimeric proteins have indicated that, similar to other ITIM-containing receptors, the cytoplasmic tail of CLEC12A can inhibit cellular activation upon ligand binding stimulation. The physiological functions of CLEC12A are poorly understood and the human ligand for CLEC12A is unknown. (7) Most CTL receptors require Ca2+ ions for binding (8). C-type lectins are the most diverse and prevalent lectin family in immunity. Particular interest has recently been attracted by the C-type lectin-like receptors on NK cells, which appear to regulate the activation/inhibitory balance of these cells, controlling cytotoxicity and cytokine production (9). CLEC12A receptor has emerged as a leukemia-associated and cancer stem cell marker in myeloid malignancies (10). CLEC12A is a myeloid lineage antigen that is highly expressed by AML cells and LSCs, but not expressed by normal hematopoietic stem cells (HSCs). The CLEC12A TriKE induced robust NK-cell specific proliferation, enhanced NK-cell activation, and killing of both AML cell lines and primary patient-derived AML blasts in vitro while sparing healthy HSCs. Additionally, the CLEC12A TriKE was able to reduce tumor burden in preclinical mouse models. These findings highlight the clinical potential of the CLEC12A TriKE for the effective treatment of AML (11).

References

  1. Lahoud, M. et al. (2009) J. Immunol. 182:7587.
  2. Pyz, E. et al. (2008) Eur. J. Immunol. 38:1157.
  3. Morsink, L. et al. (2019) Blood Reviews 34:26.
  4. Raulf, M. et al. (2019) Cell Reports 28:30.
  5. Bill, M. et al. (2019) Br. J. Haematol. 184:769.
  6. Matsuo, H. et al. (2020) Br. J. Haematol. 192:e7.
  7. Marshall, A.S. et al. (2004) J. Biol. Chem. 279:14792.
  8. Lindenwald D.L. et al. (2020) Int. J. Mol. Sci. 21:5122.
  9. Marshall, A.S. et al. (2006) Eur. J. Immunol. 36:2159.
  10. Maria, B. et al. (2018) J. Cell. Mol. Med. 22:2311.
  11. Arvindam, U.S. et al. (2021) Leukemia 35:1586.

Long Name

Myeloid Inhibitory C-type Lectin-like Receptor

Alternate Names

CD371, CLEC12A, CLL-1, DCAL-2

Entrez Gene IDs

160364 (Human); 232413 (Mouse)

Gene Symbol

CLEC12A

UniProt

AAI26292.1

Additional MICL/CLEC12A Products

Product Documents for Recombinant Human MICL/CLEC12A Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human MICL/CLEC12A Fc Chimera Protein, CF

For research use only

Customer Reviews for Recombinant Human MICL/CLEC12A Fc Chimera Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human MICL/CLEC12A Fc Chimera Protein, CF and earn rewards!

Have you used Recombinant Human MICL/CLEC12A Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

FAQs

No product specific FAQs exist for this product.

View all FAQs for Proteins and Enzymes